Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
0
users have commented on this narrative
34
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Insight Molecular Diagnostics
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Rising Global Organ Transplants Will Drive Diagnostic Testing Expansion
Key Takeaways Expanding clinical adoption and demographic trends are set to boost recurring revenue and gross margins through increased testing volume and broader market penetration. Strategic focus on high-margin digital PCR kits and new partnerships diversifies income sources, enhances profitability, and lessens dependence on external financing.
View narrative
US$5.42
FV
54.8% undervalued
intrinsic discount
32.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
15 days ago
author updated this narrative
Oncopeptides
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Agreements In Europe And Japan Will Unlock Global Markets
Key Takeaways Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth. Cost management alongside sales expansion in core European markets aims to achieve cash flow positivity, positively impacting net margins by 2026.
View narrative
SEK 2.73
FV
66.5% overvalued
intrinsic discount
121.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
15 days ago
author updated this narrative
GoPro
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Diversified Supply Chain And New Products Will Transform Digital Imaging
Key Takeaways GoPro's strategic innovations and cost reductions are expected to enhance profitability and net margins, despite market challenges and competition. New product launches and subscription service enhancements aim to drive long-term revenue and earnings growth by improving technology leadership and recurring income streams.
View narrative
US$0.98
FV
37.1% overvalued
intrinsic discount
-0.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
15 days ago
author updated this narrative
ON24
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
AI Adoption And Multi-Product Use Will Drive Future Opportunity
Key Takeaways ON24's AI and multi-product strategies drive increased adoption and revenue growth, with expanding customer usage boosting ARR and net margins. Strategic focus on regulated industries and enhanced customer retention stabilize revenue, supporting long-term profitability and cash flow.
View narrative
US$5.00
FV
4.6% overvalued
intrinsic discount
-4.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
15 days ago
author updated this narrative
Taysha Gene Therapies
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
FDA Meetings And TSHA-102 Trials Will Advance Approval
Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
View narrative
US$8.32
FV
63.6% undervalued
intrinsic discount
123.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
15 days ago
author updated this narrative
AGF Management
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Tactical Alpha And Income Funds Will Shape Future Amid Uncertainty
Key Takeaways AUM growth and fund diversification in retail mutual and alternative products signal strong potential for future revenue expansion. Strategic acquisitions and a balanced capital allocation approach, including dividend increases, promise enhanced earnings and shareholder value.
View narrative
CA$13.92
FV
14.8% undervalued
intrinsic discount
4.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
15 days ago
author updated this narrative
Cantaloupe
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Launching Capital Micro Lending Service Will Help Small And Medium Businesses
Key Takeaways Growth in micro markets and Smart Stores, along with international expansion, is driving revenue through higher transaction volumes and new market entry. Initiatives like micro-lending, digital advertising, and product innovations contribute to enhanced profitability and address capital, marketing, and operational challenges.
View narrative
US$11.20
FV
2.0% undervalued
intrinsic discount
15.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
15 days ago
author updated this narrative
Vir Biotechnology
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.
View narrative
US$17.63
FV
74.1% undervalued
intrinsic discount
40.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
15 days ago
author updated this narrative
Curtiss-Wright
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Rising Defense Budgets And Nuclear Resurgence Will Expand Opportunities
Key Takeaways Rising defense spending and nuclear sector growth are driving sustained long-term revenue and margin expansion, with strong international demand and a robust order pipeline. Focus on advanced technologies, disciplined capital allocation, and expanded shareholder returns positions the company for profitable growth and potential market undervaluation.
View narrative
US$520.33
FV
4.5% undervalued
intrinsic discount
6.76%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
Value any company in seconds
Popular companies